EOM Pharmaceutical Holdings, Inc.
EOM Pharmaceutical Holdings, Inc. (IMUC): 3 pipeline candidates · ~4 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
4.3 months
0% dilution
Lead: Phase 3
3 candidates
N/A
N/A
A transparent, data-derived signal for EOM Pharmaceutical Holdings, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$31.9M
Cash
$2.9M
Quarterly Burn
$2.2M
Runway
4.3 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Frequently asked questions
How many drug candidates are in EOM Pharmaceutical Holdings, Inc.'s pipeline?
EOM Pharmaceutical Holdings, Inc. (IMUC) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is EOM Pharmaceutical Holdings, Inc.'s lead drug candidate?
EOM Pharmaceutical Holdings, Inc.'s most advanced tracked candidate is ict-107 (Phase 3) for newly diagnosed glioblastoma.
What is EOM Pharmaceutical Holdings, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, EOM Pharmaceutical Holdings, Inc. has approximately 4.3 months of cash runway.
What is EOM Pharmaceutical Holdings, Inc.'s market capitalization?
EOM Pharmaceutical Holdings, Inc.'s market capitalization is approximately $31.9M.
Who is the CEO of EOM Pharmaceutical Holdings, Inc.?
Dr. Irach B. Taraporewala B.S., M.S., Ph.D. is the chief executive officer of EOM Pharmaceutical Holdings, Inc. (IMUC).
Get the full picture on EOM Pharmaceutical Holdings, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.